vimarsana.com
Home
Live Updates
Vaxcyte Doses First Participants in Phase 1/2 Clinical Study
Vaxcyte Doses First Participants in Phase 1/2 Clinical Study
Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults
VAX-31, a 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate, is the Broadest-Spectrum PCV to Enter the Clinic -- -- Topline Safety, Tolerability and…
Related Keywords
,
Valent Pneumococcal Conjugate Vaccine ,
Immunogenicity Data Expected ,
Second Half ,
Provide Coverage ,
Invasive Pneumococcal Disease Circulating ,
News ,
Ggregator ,
Reaking News ,
Uration ,
Media ,